Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Future Proofing & Incentives Among Industry Priorities In EU Pharma Law Shake UP

Executive Summary

Overhaul of the pharmaceutical legislation in the EU is an opportunity to learn from COVID-19, says European industry body.

You may also be interested in...



European Commission Steps Further Towards ‘Ambitious’ Pharma Legislation Reform

The incentives system, access to medicines, future proofing for novel products and antimicrobial resistance are just some of the topics included in a new consultation.

Confronting The Challenges Of Marketing Cell And Gene Therapies

The “chronic disease paradigm” presents a real challenge for companies marketing advanced therapies.

European Countries Call For Health Technology Assessments Of COVID-19 Products

Value assessments of COVID-19 monoclonal antibodies should inform pricing decisions, says cross country coalition.

Topics

UsernamePublicRestriction

Register

PS145044

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel